

Literaturverzeichnis
zum Leserbrief von Professor Dr. Tino F. Schwarz

[1] Harper D et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix 2008 (GSK HPV 16/18 AS04 candidate vaccine). Presented at: SGO's Annual Meeting on Women's Cancer. March 10, 2008 Tampa Convention Center.

[2] FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. In: N. Engl. J. Med. 2007; 356: 1915-27.

[3] Olsson SE et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. In: Vaccine. 2007; 25:4931-4939.

[4] Brown et al, ICAAC, 2007.

[5] Harper DM, Franco EL et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from aluminium control trial. The Lancet 2006; 367: 1247-1255.

[6] Paavonen, J., Jenkins, D., Bosch, X., et al. Efficacy of a human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) AS04 vaccine: a phase III randomized, controlled trial in young women, Published in June issue of Lancet 2007.